A New Strategy for Discontinuation of Dual Antiplatelet Therapy The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
- Authors
- Kim, Byeong-Keuk; Hong, Myeong-Ki; Shin, Dong-Ho; Nam, Chung-Mo; Kim, Jung-Sun; Ko, Young-Guk; Choi, Donghoon; Kang, Tae-Soo; Park, Byoung-Eun; Kang, Woong-Chol; Lee, Seung-Hwan; Yoon, Jung-Han; Hong, Bum-Kee; Kwon, Hyuck-Moon; Jang, Yangsoo
- Issue Date
- 9-Oct-2012
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- antiplatelet therapy; coronary artery disease; drug-eluting stents
- Citation
- JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.60, no.15, pp.1340 - 1348
- Journal Title
- JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Volume
- 60
- Number
- 15
- Start Page
- 1340
- End Page
- 1348
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16067
- DOI
- 10.1016/j.jacc.2012.06.043
- ISSN
- 0735-1097
- Abstract
- Objectives The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. Background There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. Methods We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES + 3-month DAPT, n = 1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n = 1,058). We hypothesized that the E-ZES + 3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel revascularization, or bleeding) at 1 year. Results The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES + 3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: -2.5 to 2.5; p = 0.84; p < 0.001 for noninferiority). The composite rates of any death, myocardial infarction, or stent thrombosis were 0.8% and 1.3%, respectively (difference: -0.5%; 95% CI: -1.5 to 0.5; p = 0.48). The rates of stent thrombosis were 0.2% and 0.3%, respectively (difference: -0.1%; 95% CI: -0.5 to 0.3; p = 0.65) without its further occurrence after cessation of clopidogrel in the E-ZES + 3-month DAPT group. The rates of target vessel revascularization were 3.9% and 3.7%, respectively (difference: 0.2%; 95% CI: -2.3 to 2.6; p = 0.70). Conclusions E-ZES + 3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079) (J Am Coll Cardiol 2012;60:1340-8) (C) 2012 by the American College of Cardiology Foundation
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16067)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.